These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Doty RL; Singh A; Tetrud J; Langston JW Ann Neurol; 1992 Jul; 32(1):97-100. PubMed ID: 1642478 [TBL] [Abstract][Full Text] [Related]
16. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Bezard E; Dovero S; Bioulac B; Gross C Exp Neurol; 1997 Nov; 148(1):288-92. PubMed ID: 9398471 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model. Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369 [TBL] [Abstract][Full Text] [Related]
18. MPTP-induced Parkinson-like disease in sheep: clinical and pathologic findings. Beale AM; Higgins RJ; Work TM; Bailey CS; Smith MO; Shinka T; Hammock BD J Environ Pathol Toxicol Oncol; 1989 Dec; 9(5-6):417-28. PubMed ID: 2637935 [TBL] [Abstract][Full Text] [Related]
19. Astrocytes and Parkinson's disease. Forno LS; DeLanney LE; Irwin I; Di Monte D; Langston JW Prog Brain Res; 1992; 94():429-36. PubMed ID: 1287728 [No Abstract] [Full Text] [Related]
20. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]